Fol. Biol. 2006, 52, 202-204
https://doi.org/10.14712/fb2006052060202
Depletion of Treg Cells Augments the Therapeutic Effect of Cancer Vaccines
References
1. , P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L., Rosenberg, S. A. (2005) Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28, 582-592.
<https://doi.org/10.1097/01.cji.0000175468.19742.10>
2. , B., Kryczek, I., Cheng, P., Zou, W., Curiel, T. J. (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 54, 369-377.
<https://doi.org/10.1111/j.1600-0897.2005.00330.x>
3. , M. J., North, R. J. (1980) T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151, 69-80.
<https://doi.org/10.1084/jem.151.1.69>
4. , J. A., Abbas, A. K. (2003) Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257.
<https://doi.org/10.1038/nri1032>
5. , I., North, R. J. (1984) Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J. Exp. Med. 159, 1312-1321.
<https://doi.org/10.1084/jem.159.5.1312>
6. , A., Rosso, O., Orengo, A. M., Di Carlo, E., Sorrentino, C., Meazza, R., Piazza, T., Valzasina, B., Nanni, P., Colombo, M. P., Ferrini, S. (2006) CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176, 1750-1858.
<https://doi.org/10.4049/jimmunol.176.3.1750>
7. , J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E., Vieweg, J. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633.
<https://doi.org/10.1172/JCI25947>
8. Elia, L., Aurisicchio, L., Facciabene, A., Giannetti, P., Ciliberto, G., La Monica, N., Palombo, F. (2006) CD4(+)CD25(+) regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther., in press.
9. , J. D., Gavin, M. A., Rudensky, A. Y. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336.
<https://doi.org/10.1038/ni904>
10. , S., Greene, M., Sehon, A. H. (1975) Immunosuppressor T cells in tumor bearing host. Immunol. Commun. 4, 201-217.
<https://doi.org/10.3109/08820137409055774>
11. , R. K., Kondo, K. (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18, 723-737.
12. , R. K., Kondo, K. (1971) Infectious immunological tolerance. Immunology 21, 903-914.
13. , S., Nomura, T., Sakaguchi, S. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061.
<https://doi.org/10.1126/science.1079490>
14. , C., Schlom, J., Camphausen, K., Coleman, C. N., Hodge, J. W. (2005) The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11, 4533-4544.
<https://doi.org/10.1158/1078-0432.CCR-04-2237>
15. , M., Yaqub, S., Johansson, C. C., Tasken, K., Aandahl, E. M. (2006) FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177, 246-254.
<https://doi.org/10.4049/jimmunol.177.1.246>
16. , F., Morosini, M., Solari, N., Passadore, I., Nascimbene, C., Novo, M., Ferrari, M, Cosentino, M., Marino, F., Pozzi, E., Fietta, A.M. (2006) Foxp3 expressing CD4+ CD25+ and CD8+CD28-T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum. Immunol. 67, 1-12.
<https://doi.org/10.1016/j.humimm.2005.11.005>
17. , H., Horikawa, T., Hara, I., Fukunaga, A., Oniki, S., Oka, M., Nishigori, C., Ichihashi, M. (2004) In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 13, 613-620.
<https://doi.org/10.1111/j.0906-6705.2004.00198.x>
18. , R. J., Bursuker, I. (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J. Exp. Med. 159, 1295-1311.
<https://doi.org/10.1084/jem.159.5.1295>
19. , S. J., Farrand, K. J., Matthews, S. A., Chang, J. H., McHugh, R. S., Ronchese, F. (2005) Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174, 90-98.
<https://doi.org/10.4049/jimmunol.174.1.90>
20. , S., Sakaguchi, N., Asano, M., Itoh, M., Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164.
<https://doi.org/10.4049/jimmunol.155.3.1151>
21. , J., Bubeník, J., Bieblová, J., Rosalia, R. A., Frič, J., Reiniš, M. (2006) Depletion of Treg cells inhibits minimal residual disease after surgery of HPV16-associated tumours. Int. J. Oncol. 29, 1567-1571.
22. , C. T., Moore, T. T., Liyanage, U. K., Frey, D. M., Ehlers, J. P., Eberlein, T. J., Goedegebuure, P. S., Linehan, D. C. (2006) Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann. Surg. Oncol. 13, 1252-1258.
<https://doi.org/10.1245/s10434-006-9015-y>
23. , T., Sakaguchi, S. (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16, 115-123.
<https://doi.org/10.1016/j.semcancer.2005.11.005>
24. , W. (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295-307.
<https://doi.org/10.1038/nri1806>
